Confirmed: the 100% tariff took effect today for the 17 companies named in Annex III. Companies not named in Annex II or III follow September 29. EU branded pharma stays capped at 15% by the trade deal regardless. Model your pharma import costs →
The 100% tariff on patented branded drugs — the single highest product-specific rate in the current US trade book — is now confirmed in force, not just threatened. Proclamation 11020 (signed April 2, 2026) phases the tariff in by company: the **17 large pharmaceutical companies named in the proclamation's Annex III hit the 100% rate today, July 31, 2026** (120 days after signing); every other company not separately named follows on **September 29, 2026** (180 days). Companies that negotiated a Commerce onshoring agreement — the application window closed June 12, 2026 — pay 20% instead of 100%; companies that also hold a most-favored-nation drug-pricing deal with HHS (13 companies, per Annex II) pay 0% until January 20, 2029. Separately, the July 1 EU-US trade deal caps **EU branded pharma at 15%**, shielding Ireland (~$50B in US-bound branded drugs) and Germany (~$14B) regardless of annex status. Switzerland ($23B) is not an EU member and stays fully exposed to the company-based rate. Generics remain outside the threat — and EU generics go MFN-only (typically 0%) on September 1. Here's what's actually in force today, what's still ahead, and how it plays out country by country.
What's Actually In Force vs. Still Ahead (July 31, 2026)
In force right now: the 17 large companies named in Proclamation 11020's Annex III pay the 100% Section 232 tariff on patented branded drugs and APIs starting today, July 31, 2026 — 120 days after the April 2 signing. EU-origin pharmaceuticals continue to pay the trade deal's 15% all-inclusive ceiling instead (since July 1, 2026 — the ceiling applies in lieu of Section 232 for pharma, regardless of a company's annex status). MFN base on chapter 30 is 0% under the WTO Pharmaceutical Tariff Elimination Agreement. Still ahead: companies not named in Annex II or III face the same 100% rate starting September 29, 2026 (180 days after signing) — that is the real date for most mid-size and smaller manufacturers, not July 31. Two relief paths already resolved before today: companies with a Commerce-approved onshoring agreement (application window closed June 12, 2026) pay 20% instead of 100%; the 13 companies in Annex II that separately signed most-favored-nation pricing agreements with HHS pay 0% until January 20, 2029. The administration's stated rationale is reshoring — and the pressure track is widening: on June 18, 2026, USTR opened a Section 301 investigation against Germany over persistent underpayment for innovative pharmaceutical products.
Why Pharma Has Been Duty-Free Since 1995
The WTO Pharmaceutical Tariff Elimination Agreement of 1995 — signed by the US, EU, Japan, Switzerland, and others — eliminated MFN duty on roughly 7,000 pharmaceutical products in chapter 30. The Section 122 layer added 10% in February 2026 — the first US import duty on pharma in 30+ years. A 100% Section 232 layer on top would be the biggest reversal since the agreement was signed. The legal authority works because Section 232 supersedes the WTO commitment when invoked on national security grounds.
Advertisement
Worked Example: $1M Branded Drug Shipment from Ireland vs. Switzerland
A $1,000,000 CIF shipment of a patented branded drug from a Pfizer facility in Cork, Ireland, classified under HTS 3004.90 (other medicaments, retail-packaged). MFN: 0%. Since July 1, 2026, the EU deal's 15% ceiling governs: $150,000. MPF capped at $634.62 per entry, HMF at 0.125% = $1,250. Total duty: roughly $151,885 — effective rate about 15.2%, and capped there regardless of the company's Annex II/III status. Now run the identical $1M shipment from a Roche facility in Basel, Switzerland — not an EU member, not covered by the deal. If the manufacturer has a Commerce onshoring agreement: 20% = $200,000. If it's named in Annex III and doesn't: 100% starting July 31, 2026 = $1,000,000 of duty on a $1M shipment. If it's not named in Annex II or III at all, that 100% exposure starts later, September 29, 2026. The Ireland-vs-Switzerland delta under the worst case is roughly $850,000 per container on identical molecules — the deal turned EU origin into pharma's most valuable sourcing attribute.
Generics, APIs, and Medical Devices Stay Different
Generic drugs pay the base reciprocal forced-labor tariff — 10% or 12.5% depending on origin (India, the largest generic source, is in the 12.5% tier) — on top of 0% MFN. The 100% rate is patent-specific. Active pharmaceutical ingredients (APIs, HTS 2941 and 2942) pay the same base reciprocal forced-labor tariff plus 0% MFN — same as generics. Medical devices (chapter 90) are excluded from chapter 30 and have their own MFN structure: most diagnostic equipment is 0%, surgical instruments 0%, dental equipment 0-2%. So the 100% threat does not hit Indian generic exporters (Cipla, Dr. Reddy's, Sun Pharma), it does not hit Chinese API producers (Section 301's separate 25% Chinese layer applies, putting Chinese APIs at 37.5% combined — 12.5% base + 25% Section 301), and it does not hit medical device makers in Ireland or Germany. The 100% rate is a precision instrument aimed at branded patent-holding manufacturers — primarily US firms producing offshore to capture Irish and Swiss tax treatment.
Country Exposure: The EU Deal Redrew the Map
Ireland ships roughly $50B in pharma to the US annually, primarily branded patented drugs from Pfizer, Eli Lilly, AbbVie, Merck, and Johnson & Johnson facilities operating under Ireland's 12.5% corporate tax rate — and as of July 1, 2026, all of it is capped at 15% by the EU-US trade deal. Germany's ~$14B (Bayer, Boehringer Ingelheim) gets the same 15% cap, though Germany now faces a separate USTR Section 301 investigation (opened June 18, 2026) over underpayment for innovative drugs. Switzerland is the exposed one: ~$23B dominated by Roche and Novartis, not an EU member, not covered by the deal — Swiss branded pharma faces 20% with a Commerce onshoring agreement or 100% without one, on whichever effective date applies to that manufacturer (July 31 if named in Annex III, September 29 otherwise). India is the largest source of generic dose volume (~$9B, almost all generic) and stays outside the branded tariff entirely. China runs ~$2.5B mostly in APIs (35% effective with Section 301). The bottom line: the 100% tariff is now effectively a Switzerland-and-everyone-else problem, not an Ireland problem.
July 31 Is an Effective Date, Not a Negotiating Deadline
Two dates matter here and they're easy to conflate. The onshoring negotiation window — Commerce's application process for companies wanting the 20% rate — closed June 12, 2026; that deadline has passed. July 31, 2026 is a separate, later date: the day the 100% tariff actually takes effect for the 17 companies named in the proclamation's Annex III (120 days after the April 2 signing). Companies that secured an onshoring agreement before the June 12 deadline pay 20% starting from their agreement's terms; companies that didn't and are named in Annex III pay 100% starting today. Everyone else not named in Annex II or III gets a longer runway — their effective date is September 29, 2026 (180 days after signing). EU-origin branded pharma is capped at 15% by the trade deal regardless of annex status; EU generics, APIs, and chemical precursors go MFN-only (typically 0%) on September 1; and generics from any origin stay outside the branded threat entirely.
What This Does to US Drug Prices
A 100% tariff flows into US patient prices — eventually. Drug companies pay duty at the port (the importer is usually the US sales sub of the multinational), and the duty becomes a cost of goods. On patented drugs with no generic competition, pricing power is high — 70-90% pass-through to commercial insurers and patient out-of-pocket over 12-24 months. Medicare Part D and Medicaid pricing is partly constrained by IRA negotiations, but rebates work off list price, and list prices reset upward to absorb the duty. US branded drug spending runs about $400B a year. The EU deal's 15% cap sharply reduces the worst case — roughly two-thirds of US-bound branded pharma value (Ireland, Germany, and other EU origins) is now capped at 15% rather than exposed to 100% — leaving the heaviest price pressure concentrated in Swiss-origin and other non-EU branded product without an onshoring agreement. The administration's counter is reshoring — but reshoring a major facility runs 5-7 years and tens of billions in capex. Duty is already hitting Annex III companies as of July 31, 2026; reshoring offset arrives 2031 at the earliest.
What Importers Should Do This Week
Step 1: Sort every pharma SKU by origin and by manufacturer — EU branded product is capped at 15% by the trade deal regardless; non-EU branded product (Switzerland foremost) now carries live exposure. Step 2: Confirm whether your supplier is named in Annex III (100% effective today, July 31) or falls under the September 29 date instead, and whether they hold an onshoring agreement (20%) or MFN pricing deal (0% until 2029). Step 3: For non-EU branded imports without a confirmed exemption, model landed cost at both 20% and 100% on Q3-Q4 2026 forecasts. Step 4: For EU generic and API lines, model the September 1 MFN-only shift — near-0% duty makes delaying non-urgent shipments worth real money. Step 5: For API buyers, Chinese APIs remain at 37.5% effective with Section 301 and carry separate escalation risk. Step 6: Confirm patent status on every imported SKU — a branded-vs-generic indicator drives rate treatment on entries now that the tariff is live for some manufacturers.
Key Takeaway
Trump's pharma tariff structure has three tiers: EU branded pharma capped at 15% by the trade deal effective July 1 regardless of manufacturer; non-EU branded drugs facing 20% (with an onshoring agreement) or 100% (without one, on the manufacturer's applicable effective date — July 31 for the 17 Annex III companies, September 29 for everyone else); and generics outside the tariff entirely, with EU generics going MFN-only on September 1. Ireland and Germany are shielded; Switzerland takes the hardest exposure; India's generics business stays insulated. The 100% rate is now live for the largest branded manufacturers, so pharma importers should confirm their suppliers' annex status and reprice non-EU branded SKUs now rather than waiting for September 29.
Calculate Your Import Duty
Get an instant estimate for your specific product, country, and shipment value.
Open the US Import Duty CalculatorAdvertisement